Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.
·The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and placebo respectively. ·Estimates for the opioid sparing effect of ketamine showed a need for more than double the sufentanil exposure to get the same overall effect seen with the treatment of CT001. ·The data supports the earlier reported data from the Dental Study 0205 showing the effectiveness of treatment with CT001. The full simulated data set will be presented at the PAGE conference in Rome 26-28 June.On 3 June – Cessatech A/S (“Cessatech”